Product Description: Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.
Applications: Neuroscience-Neuromodulation
Formula: C25H34FN3O2
Citations: ACS Chem Neurosci. 2019 Nov 20;10(11):4476-4491. /bioRxiv. 2020 Feb./Department Neuroscience. Virginia Commonwealth University. 2016 Oct./Int J Clin Exp Med. 2019;12(8):10342-10349/Int J Neuropsychopharmacol. 2021 Jul 6;pyab040./J Med Chem. 2023 Jun 28./Patent. US20200352950A1./Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26438-26447./Sci Rep. 2024 Jan 16;14(1):1396./bioRxiv. 2023 Jul 31./Food Chem Toxicol. 2023 Apr 24;113800./Nat Commun. 2023 Dec 15;14(1):8221.
References: [1]Vanover KE, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8./[2]Vanover KE, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4.
CAS Number: 706779-91-1
Molecular Weight: 427.55
Compound Purity: 99.86
Research Area: Neurological Disease
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: 5-HT Receptor
English
Deutsch
